Indivisible Partners’s Allogene Therapeutics ALLO Stock Holding History

Indivisible Partners’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$235K	Buy	+147,000	New	+$280K	0.01%	655

Other funds holding ALLO

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

OpenArc Corporate Advisory Atlanta, Georgia $8.86B AUM 19.31% 1-Year Est. Return

Bourgeon Capital Management Darien, Connecticut $696M AUM 39.92% 1-Year Est. Return

Vontobel Holding Zurich, Switzerland $27.7B AUM 21.75% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

Regatta Capital Group El Segundo, California $791M AUM 15.21% 1-Year Est. Return

Investment House LLC Redondo Beach, California $2.25B AUM 30.44% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

Shikiar Asset Management New York $398M AUM 33.64% 1-Year Est. Return

Indivisible Partners's ALLO Position: Q3 2026 in Review

Indivisible Partners opened a new position in Allogene Therapeutics (ALLO) in Q3 2026: 147,000 shares worth $235K. The stake represents 0.01% of the portfolio and ranks #655 among its holdings.

26 funds tracked by Wall St. Rank hold ALLO as of Q3 2026.

Indivisible Partners held 147,000 shares of Allogene Therapeutics worth $235K as of Q3 2026.
Allogene Therapeutics was a new Indivisible Partners position in Q3 2026.
Allogene Therapeutics made up 0.01% of Indivisible Partners's portfolio in Q3 2026, its #655 holding.
26 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q3 2026.

Based on Indivisible Partners's 13F filing for Q3 2026, filed 26 Oct 2026.